Last reviewed · How we verify
immediate treatment with corticosteroids
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Corticosteroids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute ocular inflammation (specific indication not detailed in source).
At a glance
| Generic name | immediate treatment with corticosteroids |
|---|---|
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids are potent anti-inflammatory agents that work by translocating to the nucleus and modulating gene expression of inflammatory mediators. They reduce immune cell activation, decrease vascular permeability, and suppress cytokine release. In ophthalmology, they are used to rapidly control ocular inflammation and immune-mediated conditions.
Approved indications
- Acute ocular inflammation (specific indication not detailed in source)
Common side effects
- Elevated intraocular pressure
- Cataract formation
- Secondary infection
- Local irritation
Key clinical trials
- Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis (NA)
- Steroid Sparing in Immune Related Hepatitis (irH) (NA)
- Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PHASE4)
- 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study (NA)
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (PHASE4)
- Fractional Exhaled Nitric Oxide and Exacerbations of COPD
- Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial. (PHASE3)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: